Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
Retrieved on:
Tuesday, April 25, 2023
Amyloid-related imaging abnormalities, PMN, Plaque, Therapy, PROMIS, Vaccination, AAN, American Academy, Multiple system atrophy, QS-21, Brain, Biomarker, Meningoencephalitis, ARIA, Patient, MSA, Risk, KLH, Annual general meeting, Neuroscience, Epitope, TSX, AD, American Academy of Neurology, Immunization, ALS, Disease, Vaccine
An AD vaccine capable of inducing an effective antibody response against pathogenic Aβ could potentially be administered as a preemptive measure to at-risk individuals to prevent the symptomatic disease or given therapeutically to diagnosed patients to inhibit the progression of AD.
Key Points:
- An AD vaccine capable of inducing an effective antibody response against pathogenic Aβ could potentially be administered as a preemptive measure to at-risk individuals to prevent the symptomatic disease or given therapeutically to diagnosed patients to inhibit the progression of AD.
- Using computational modeling, ProMIS has identified conformational epitopes that are exposed on misfolded, toxic Aβ oligomers (AβO), the driver of disease, and not on monomers or plaque.
- There were no potentially deleterious T helper cell responses to the conformational AβO peptide epitope, and T helper responses developed only against the KLH carrier protein.
- These findings support potential clinical development of a therapeutic vaccine for AD that could elicit an antibody response while reducing the risk of meningoencephalitis, as well as ARIA.